Please type a plus sign (+) inside this box -> -	\mp
--	-------

				Complete if Known		
Substitute for form 1449A/B/PTO				Application Number	10/588,323	
INFORMATION DISCLOSURE			CLOSURE	Filing Date	February 16, 2007	
STATEMENT BY APPLICANT				First Named Inventor	Daniel Magilavy	
				Group Art Unit	1644	
(Use as many sheets as necessary)			cessary)	Examiner Name	Phillip Gambel	
Sheet	1	of	1	Attornev Docket Number	253780 (A224)	

		OTHER - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation *
	C627	BIOGEN IDEC, Safety Letter, Cambridge, MA (October, 2005)	
	C628	CIPO, Official communication relative to related Canadian Application No. 2,565,259 mailed April 30, 2009	
	C629	CIPO, Official communication relative to related Canadian Application No. 2,454,618 mailed May 1, 2009	
	C630	CIPO, Official communication relative to cognate Canadian Application No. 2,555,144 mailed August 13, 2009	
	C631	EPO, Official communication relative to related European Application No. 05779311.9 mailed January 29, 2008	
	C632	EPO, Official communication relative to related European Application No. 05779971.0 mailed July 24, 2008	
	C633	EPO, Official communication relative to related European Application No. 02749865.8 mailed May 8, 2009	
	C634	GORDON et al., Remittive effects of intramuscular alefacept in psoriasis, Journal of Drugs in Dermatology, 2:6:624-628 (2003)	
	C635	MAGILAVY et al., <i>Journal of Investigative Dermatology</i> , 110(4): 682 (Abstract 1260), (April 1998)	
	C636	MILLER et al., Specific interaction of lymphocyte function-associate antigen 3 with CD2 can inhibit T cell responses, <i>Journal Exp. Medicine</i> , The Rockefeller University Press, 178: 211-222 (July 1993)	
	C637	Submission Accompanying a Request for Continued Examination filed in related U.S. Application No. 11/398,908 on September 15, 2009	
	C638	USPTO, Office Action in related U.S. Application No. 10/484,329 mailed December 24, 2008	
	C639	USPTO, Office Action in related U.S. Application No. 11/578,391 mailed February 4, 2009	

Examiner Signature	Date Considered	

^{*} If the reference is not in English, then at least one of the following is provided: (a) an English translation in whole or in part or (b) a concise statement of relevance in the form of, for example, an English language counterpart, an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office.